A Prospective Clinical Trial of Preliminary Efficacy and Safety of the Combination of 177Lu-FAP-2286 and 177Lu-DOTATATE (Cocktail Therapy) for Advanced Grade 3 Gastroenteropancreatic Neuroendocrine Tumors (FAP-TATE Trial) (ChiCTR) - Oct 16, 2026 - P=N/A | N=20 | Not yet recruiting | Sponsor: The affiliated hospital of southwest medical university; The affiliated hospital of southwest medical university
New trial • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor
|